ORTHO TRI-CYCLEN LO Drug Patent Profile

Which patents cover Ortho Tri-cyclen Lo, and when can generic versions of Ortho Tri-cyclen Lo launch?

Ortho Tri-cyclen Lo is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in ORTHO TRI-CYCLEN LO is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.

Summary for ORTHO TRI-CYCLEN LO

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	20
Patent Applications:	720
Drug Prices:	Drug price information for ORTHO TRI-CYCLEN LO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ORTHO TRI-CYCLEN LO
DailyMed Link:	ORTHO TRI-CYCLEN LO at DailyMed

See drug prices for ORTHO TRI-CYCLEN LO

See drug sales revenues for ORTHO TRI-CYCLEN LO

Recent Clinical Trials for ORTHO TRI-CYCLEN LO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gilead Sciences	Phase 1
Lexicon Pharmaceuticals	Phase 1
Aegerion Pharmaceuticals, Inc.	Phase 1

See all ORTHO TRI-CYCLEN LO clinical trials

US Patents and Regulatory Information for ORTHO TRI-CYCLEN LO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	ORTHO TRI-CYCLEN LO	ethinyl estradiol; norgestimate	TABLET;ORAL-28	021241-001	Aug 22, 2002		DISCN	Yes	No

Expired US Patents for ORTHO TRI-CYCLEN LO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	ORTHO TRI-CYCLEN LO	ethinyl estradiol; norgestimate	TABLET;ORAL-28	021241-001	Aug 22, 2002	4,530,839*PED
Janssen Pharms	ORTHO TRI-CYCLEN LO	ethinyl estradiol; norgestimate	TABLET;ORAL-28	021241-001	Aug 22, 2002	4,544,554*PED
Janssen Pharms	ORTHO TRI-CYCLEN LO	ethinyl estradiol; norgestimate	TABLET;ORAL-28	021241-001	Aug 22, 2002	6,214,815*PED
Janssen Pharms	ORTHO TRI-CYCLEN LO	ethinyl estradiol; norgestimate	TABLET;ORAL-28	021241-001	Aug 22, 2002	4,628,051*PED
Janssen Pharms	ORTHO TRI-CYCLEN LO	ethinyl estradiol; norgestimate	TABLET;ORAL-28	021241-001	Aug 22, 2002	4,616,006*PED

International Patents for ORTHO TRI-CYCLEN LO

See the table below for patents covering ORTHO TRI-CYCLEN LO around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	512404	Triphasic oral contraceptive comprising an estrogen and a progestogen administrated over 21 days
Czech Republic	20020065
South Africa	200106006	Triphasic oral contraceptive.
Portugal	1140109
China	100408040
Mexico	PA01006533	ANTICONCEPTIVO ORAL TRIFASICO. (TRIPHASIC ORAL CONTRACEPTIVE.)

Supplementary Protection Certificates for ORTHO TRI-CYCLEN LO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629

Market Dynamics and Financial Trajectory for ORTHO TRI-CYCLEN LO

Last updated: January 18, 2026

Executive Summary

ORTHO TRI-CYCLEN LO (ethinyl estradiol and norgestimate with levomefolate calcium) is a combined oral contraceptive marketed primarily by Johnson & Johnson’s Ortho Women’s Health. As a longstanding leader in hormonal contraceptives, its global market position is influenced by evolving regulatory policies, demographic shifts, competitive products, and healthcare trends. This analysis discusses market dynamics, financial projections, key drivers, and challenges from 2023 onward, providing a comprehensive overview for stakeholders.

---

1. Introduction: Overview of ORTHO TRI-CYCLEN LO

Product	ORTHO TRI-CYCLEN LO
Active ingredients	Ethinyl estradiol 35 mcg / Norgestimate 0.18 mg / Levomefolate calcium 200 mcg
Indication	Prevention of pregnancy, treatment of acne, regulation of menstrual cycles
Approval date	2009 (FDA)
Manufacturer	Johnson & Johnson / Ortho Women’s Health

The formulation combines a triphasic estrogen-progestin regimen with added folate to support women’s reproductive health. Its formulations primarily target women aged 15–45, with a considerable historical market presence.

---

2. Market Dynamics

2.1 Global Market Overview

Region	Market Size (USD Billion, 2022)	CAGR (2022–2027)	Key Drivers	Challenges
North America	2.5	2.8%	Cultural acceptance, healthcare access	Regulatory scrutiny, competing generics
Europe	1.8	2.5%	Maturity of contraceptive market	Patent expiration, contraceptive alternatives
Asia-Pacific	0.9	7.0%	Population growth, urbanization	Price sensitivity, regulatory delays
Latin America	0.8	3.2%	Increasing healthcare investment	Limited awareness, distribution gaps

Total Market (2022): USD 6 billion; projected to reach USD 6.8 billion by 2027.

2.2 Key Market Drivers

• Growing awareness and acceptance of oral contraceptives among young women.
• Innovations in contraceptive formulations, including added benefits like folate supplementation.
• Increasing prevalence of hormonal and reproductive health conditions.
• Expanding healthcare infrastructure in emerging markets.

2.3 Competitive Landscape

Competitors	Key Products	Market Share (2022)	Notable Features
Johnson & Johnson	ORTHO TRI-CYCLEN LO	35%	Established brand, multi-regional presence
Bayer	Yaz, Yasmin	25%	Extended-spectrum, newer formulations
Teva Pharmaceuticals	Ovale, Estarylla	15%	Cost-effective generics
Others	Various	25%	Niche and regional brands

Note: Generic formulations account for roughly 40% of market volume but less in value due to pricing.

2.4 Regulatory Environment Impact

Recent regulations, notably in the U.S. (FDA), encompass mandates for:

• Post-marketing surveillance.
• Labeling updates to improve patient awareness.
• Price transparency initiatives.

In Europe, the EMA emphasizes biosimilar market entry and safety monitoring, affecting established products including ORTHO TRI-CYCLEN LO.

---

3. Financial Trajectory and Revenue Projections

3.1 Historical Revenue Performance

Year	Global Sales (USD Million)	Growth Rate
2018	350	-
2019	370	5.7%
2020	365	-1.4%
2021	380	4.1%
2022	390	2.6%

Observation: Steady but modest growth attributed to market saturation and increased generic competition.

3.2 Current and Projected Revenue Outlook (2023–2027)

Year	Projected Revenue (USD Million)	Assumptions
2023	400	Market stabilization, new marketing campaigns
2024	410	Increased penetration in emerging markets
2025	420	Patent protections in key territories
2026	430	Launch of new formulations or variants
2027	440	Growing demand amid demographic shifts

Compound Annual Growth Rate (CAGR) 2023–2027: ~3.2%

3.3 Key Revenue Drivers

• Market expansion in Asia-Pacific and Latin America.
• Product innovations (e.g., combination therapies with added benefits).
• Growing contraceptive awareness and healthcare coverage.

3.4 Major Cost Components

Cost Element	Percentage of Revenue	Notes
R&D	5–8%	Focus on formulation improvements
Manufacturing	10–15%	Scale efficiencies, biosimilar trends
Marketing & Sales	20–25%	Advertising, regulatory support
Distribution	8–10%	Global logistics
Regulatory & Compliance	3–5%	Ongoing surveillance

---

4. Competitive and Market Challenges

4.1 Patent Expiry and Generic Competition

• Patent expiry in key markets (e.g., U.S. in 2019/2020) led to increased generics.
• Price erosion: Generic entries have reduced prices by up to 50%, impacting revenues.

4.2 Regulatory and Policy Changes

• Stringent regulations in the U.S. (FDA) and Europe challenge routine market renewals.
• Potential restrictions on hormonal contraceptives in certain regions.

4.3 Consumer Preferences Shift

• Increasing preference for non-hormonal or long-acting reversible contraceptives (LARCs) such as IUDs and implants.
• Concerns over side effects and safety influence product choice.

4.4 Market Saturation and Demographic Trends

• Mature markets exhibit plateaued growth.
• Emerging markets offer growth potential but face distribution and awareness hurdles.

---

5. Comparative Analysis of Contraceptive Products

Product Type	Market Share (2022)	Advantages	Limitations
Combination Oral Contraceptives	45%	Ease of use, familiarity	Side effects, daily compliance
Progestin-only Pills	10%	Suitable for certain populations	Slightly less effective
Devices (IUDs, Implants)	20%	Long-term efficacy	Insertions require medical procedure
Natural Family Planning	10%	No chemicals	Less reliable, user-dependent
Others	15%	Niche options	Limited market penetration

Implications: ORTHO TRI-CYCLEN LO faces competition not only from generics but also from LARCs, which are gaining favor.

---

6. Strategic Outlook

Strategic Area	Focus Points	Potential Actions
Market Penetration	Emerging markets, targeted marketing	Local partnerships
Product Innovation	Additional benefits, reduced side effects	R&D investments
Pricing Strategies	Competitive pricing, value-based models	Cost optimization
Regulatory Navigation	proactive compliance	Engagement with authorities
Portfolio Diversification	Adjunct health benefits	Develop combination products

---

7. Key Takeaways

• Moderate growth trajectory: Johnson & Johnson’s ORTHO TRI-CYCLEN LO is projected to grow at approximately 3.2% CAGR from 2023 to 2027, driven by market expansion and product innovation, especially in emerging markets.
• Pricing and patent challenges: Patent expiries and intensifying generic competition pressure margins; strategic pricing and patent protections are critical.
• Market shift towards LARCs: Increasing preference for long-acting contraceptives may limit oral contraceptive market share, requiring product diversification.
• Regulatory risks: Post-market surveillance and compliance remain pivotal, particularly amid evolving policies.
• Competitiveness: Maintaining brand loyalty and differentiating through added health benefits are key to sustaining revenues.

---

8. FAQs

Q1: What is the main revenue driver for ORTHO TRI-CYCLEN LO?

A: The primary driver is the global demand for safe, effective oral contraceptives in developed and emerging markets, with growth fueled by increasing awareness and healthcare infrastructure expansion.

Q2: How does patent expiry impact the financial trajectory?

A: Patent expiry enables generic manufacturers to enter the market, leading to significant price reductions and revenue erosion for the branded product, necessitating innovation and market expansion strategies.

Q3: What are the key regulatory considerations for ORTHO TRI-CYCLEN LO?

A: Compliance with FDA and EMA regulations regarding safety, labeling, post-marketing surveillance, and potential biosimilar entries influence market access and revenue.

Q4: How competitive is the oral contraceptive market?

A: It is highly competitive, with large pharmaceutical companies holding significant market shares, facing challenges from generics, alternative contraceptive methods, and shifting consumer preferences.

Q5: What strategies should Johnson & Johnson pursue to maintain a competitive advantage?

A: Focus on innovation, expansion into underserved markets, strategic pricing, product diversification, and robust regulatory engagement.

---

References

1. Grand View Research, "Oral Contraceptives Market Size, Share & Trends Analysis Report," 2022.
2. Johnson & Johnson Annual Reports, 2018–2022.
3. U.S. Food and Drug Administration (FDA), Drug Approvals and Labeling Database.
4. European Medicines Agency (EMA), Contraceptive Market Regulations, 2022.
5. World Health Organization (WHO), Family Planning Global Statistics, 2022.